Ocular Pharmacology and Drug Delivery examines the discovery, development, administration, safety, and effectiveness of therapies for eye disease. The session includes conventional and novel drugs, biologics, sustained-release systems, targeted delivery, intraocular therapies, pharmacokinetics, toxicity, and innovative platforms designed to improve therapeutic effectiveness.
Abstract Scope and Participation
Submissions may cover drug discovery, ocular therapeutics, pharmacology, formulation, biologics, delivery systems, safety, pharmacokinetics, clinical trials, and treatment outcomes. Pharmacologists, ophthalmologists, pharmaceutical scientists, researchers, clinicians, biomedical engineers, and industry professionals are invited to participate.
Background and Aims: To address the limitations of conventional postoperative eye drop regimens following cataract surgery, we developed an acid-sensitive prodrug-based Microcrystals (MCs) of…
Despite progress in the management of patients with retinal vascular and degenerative diseases, there is still an unmet clinical need for safe and effective therapeutic options with novel mechanisms…
In clinical practice, anti-vascular endothelial growth factor (VEGF) therapies have been successfully applied to patients with neovascular eye diseases. However, unmet clinical needs have not yet…
Choroidal neovascularization (CNV) is a major cause of blindness in ocular fundus disease. The major defects of the current first-line anti-VEGF drugs for fundus disease are the high administration…
We invented a novel resistance sensing mechanical principle which enables precise injection of flowable material into the superachoroidal space. Based on this principle, after three generations of…
The current study aims to compare outcomes of diclofenac versus corticosteroids following strabismus surgery. A systematic review and meta-analysis were performed in line with the PRISMA guidelines.…
Sessions are CPD-accredited by The CPD Group (UK) — one CPD credit for every hour of attendance.
Oral and poster slots for original Ocular Pharmacology and Drug Delivery work, reviewed by the scientific committee.
Meet ophthalmologists, vision scientists, and eye-care clinicians from around the world across three days.
Accepted abstracts are compiled into the conference proceedings and indexed in Scopus and Web of Science.
Plenary lectures from leading voices shaping Ocular Pharmacology and Drug Delivery research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Ocular Pharmacology and Drug Delivery track is a dedicated stream within IOC 2027 covering the latest research, clinical innovation, and best practice in Ocular Pharmacology and Drug Delivery. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Ophthalmologists, optometrists, vision scientists, educators, doctoral students, and trainees with an interest in Ocular Pharmacology and Drug Delivery are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IOC 2027 is a hybrid conference — attend the Ocular Pharmacology and Drug Delivery track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
